The use of phosphodiesterase 5 inhibitors with concomitant medications.
The phosphodiesterase-5 inhibitors (PDE5i) sildenafil, vardenafil, and tadalafil are considered first-line therapy for the treatment of patients with erectile dysfunction (ED). In addition to the classical pro-erectile-effect, clinical findings have suggested that they can also influence vascular tone in pulmonary, coronary and other vascular tissues, as well as improving symptoms associated with benign prostatic hyperplasia. Therefore, considering the hypothetical widespread application of PDE5i, the potential for drug-drug interactions emerges as a relevant factor in determining the safety profile of PDE5i. Review of relevant literature was conducted using data sources from MEDLINE (1998, to June 2007). The use of nitrates remains the only contraindication for all 3 PDE5i. Vardenafil is also not recommended in patients taking type 1A (such as quinidine, or procainamide) or type 3 antiarrhythmics (such as sotalol, or amiodarone) while no other major limitations have been reported for tadalafil and sildenafil. In contrast to previously reported labeling, recent studies have suggested only a precaution, but not contraindication with the concomitant use of alpha-blockers agents. In addition, precaution is also suggested in the presence of potent CYP3A inhibitors, such as azole antifungals, antiretroviral protease inhibitors, or macrolid antibiotics. This is because sildenafil, vardenafil, and tadalafil are metabolized mainly via the CYP3A4 pathway. On the other hand, statins and testosterone seem to have synergic effects with PDE5i on sexual activity.
Corona
G
G
Andrology Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.
Razzoli
E
E
Forti
G
G
Maggi
M
M
D000890:Anti-Infective Agents / Q000494:pharmacology; D000927:Anticonvulsants / Q000494:pharmacology; D000928:Antidepressive Agents / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology; D004347:Drug Interactions; D007172:Erectile Dysfunction / Q000188:drug therapy; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D002317:Cardiovascular Agents; D006635:Histamine H2 Antagonists; D007004:Hypoglycemic Agents; D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents